Insulet (Nasdaq:PODD) announced today that it appointed Cristal Downing as its new chief corporate affairs officer, effective today. In the newly created role at the automated insulin delivery system developer, Downing will build and lead a corporate affairs function aimed at strengthening Insulet’s corporate reputation, advancing business priorities, catalyzing customer value and deepening engagement with […]
Insulet
Insulet wins FDA clearance for Omnipod 5 algorithm enhancements
Insulet (Nasdaq:PODD) announced today that it received FDA 510(k) clearance for new enhancements to its Omnipod 5 system. The Acton, Massachusetts–based company said the updates to its tubeless, wearable automated insulin delivery patch pump’s algorithm include a new benchmark in tubeless diabetes technology with a lower, 100 mg/dL target glucose option. It also delivers a […]
Insulet makes Omnipod 5 available with Dexcom G7 15 Day CGM
Insulet (Nasdaq:PODD) today announced immediate compatibility between its Omnipod 5 system and the Dexcom (Nasdaq:DXCM) G7 15 Day CGM. Acton, Massachusetts-based Insulet, which has paired its pumps with previous versions of Dexcom continuous glucose monitors (CGMs), has offered Omnipod 5 with the initial version of G7 since early 2024. However, Dexcom received FDA clearance for people […]
Insulet CEO Ashley McEvoy lays out plans for Omnipod 6, innovation roadmap
Insulet (Nasdaq:PODD) today hosted its Investor Day, led by President and CEO Ashley McEvoy, laying out the future for the insulin pump maker. McEvoy, who assumed the corner office six months ago, has recently spoken about the company’s use of artificial intelligence to advance its automated insulin delivery (AID) offerings, while competition continues to heat […]
Insulet to launch next-gen Omnipod 6 in 2027, outlines plans for fully closed loop pump for type 2
Insulet (Nasdaq:PODD) today revealed plans for its innovation pipeline, which includes the next-generation Omnipod 6 system. At the company’s Investor Day event, held at its Acton, Massachusetts headquarters, President and CEO Ashley McEvoy laid out the company’s innovation roadmap. That includes updates to the current-generation Omnipod 5 platform, the new Omnipod 6 and a new, […]
What diabetes tech companies are doing on World Diabetes Day 2025
Once again, World Diabetes Day, celebrated on Nov. 14 every year, has come around, highlighting new initiatives in the diabetes tech space. The date marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness Month. […]
Insulet leadership talks patch pump competition, expanding type 2 diabetes market
As Insulet (Nasdaq:PODD) continues to grow in its leadership position within the insulin patch pump market, other entries could be on the way. The Acton, Massachusetts–based company’s Omnipod platform has long been the leader in the patch pump space, with the latest-generation Omnipod 5 delivering nearly $700 million in revenue in the company’s recently announced […]
Insulet increases guidance again on Q3 beats, 30% sales uptick
Insulet (Nasdaq:PODD) shares rose slightly before hours today on third-quarter results that landed well ahead of the consensus forecast. Shares of PODD ticked up 2.4% to $322 apiece in pre-market trading today. The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $87.6 million. That equals $1.24 per share on sales of $706.3 million […]
Insulet launches inclusion campaign for Diabetes Awareness Month
Insulet (Nasdaq:PODD) today announced a new Diabetes Awareness Month campaign called “The Day Diabetes Showed Up to Work.” The American Diabetes Association (ADA) Diabetes Awareness Month begins on Nov. 1. World Diabetes Day is also coming up on Nov. 14, marking the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles […]
Insulet adds JPMorgan veteran to its board of directors
Insulet (Nasdaq:PODD) announced today that it appointed Robert “Robbie” L. Huffines to its board of directors. Huffines, a former global chair of investment banking at JPMorgan Chase & Co., joins the automated insulin delivery technology maker’s board effective Oct. 31, 2025. He joins as an independent director and a member of the Insulet Audit Committee. […]
